FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308134630> ?p ?o ?g. }

• W4308134630 endingPage "A585" @default.
• W4308134630 startingPage "A584" @default.
• W4308134630 abstract "Abstract Introduction Changes in the expression of microRNA facilitate in the formation of various tumors. MEN1 is a rare disease caused by mutations in MEN1 gene encoding the menin protein and characterize by the occurrence of parathyroid, pituitary, gastroenteropancreatic and other tumors. If a patient with the MEN1 phenotype carry no mutations in the MEN1 gene, the condition considers a phenocopy of syndrome (phMEN1). We hypothesize that the pathogenic link among the above sporadic tumors might be represented by molecular pathways involving the MEN1 gene and epigenetic regulations — particularly microRNAs. Materials & methods Single-center, case-control study: assessment of plasma microRNA expression in patients with phMEN1, acromegaly (AM), primary hyperparathyroidism (PHPT) and healthy controls. Morning plasma samples were collected from fasting patients and age- and sex-matched controls and stored at –80°C. Total RNA isolation: miRNeasy Mini Kit with QIAcube. The libraries were prepared by the QIAseq miRNA Library Kit following the manufacturer. Circulating miRNA sequencing was done on Illumina NextSeq 500 (Illumina). Subsequent data processing was performed using the DESeq2 bioinformatics algorithm. Results We enrolled 36 consecutive patients (12 patients in each group) with phMEN1, AM, PHPT, along with 12 age and gender matched controls. Median age of phMEN1 group — 59 [52; 60.5]; AM — 59 [52; 63]; PHPT — 60.5 [54; 62.5]; control — 59 [51.5; 62.5]. The groups did not differ in age (p=0.88) and gender – in all groups were 11 women and 1 man (p=1.00). We divided all assessed microRNAs into 3 groups based on the significance of the results; the first group consisted of samples with the highest levels of detected microRNAs (&gt;50), the second group — moderate (10–50), the third group — the lowest (&lt;10). The microRNA expression pattern was almost the same between AM and phMEN1 groups (15 microRNAs upregulated, 10 — downregulated), we found slightly decreased hsa-miR-4301 (padj=0.038); it is interesting that phMEN group when compared to PHPT and control groups showed decline in hsa-miR-4301 too. PHPT and control groups had also quite similar expression profile (4 microRNAs upregulated, 19 — downregulated). 607 microRNA were differently expressed in groups phMEN1 and PHPT (473 upregulated microRNAs, 134 — downregulated). We found increased expression of some microRNAs that interferes with menin: hsa-miR-24-1-5p (padj=0.0008), hsa-miR-24-3p (padj=0.034), hsa-miR-26a-5p (padj=0.0005), hsa-miR-421 (padj=0.018), hsa-miR-762 (padj=0.027). In addition, we found decreased microRNAs with oncogene potential: miR-3182 (padj=0.007), hsa-miR-875-5p (padj&lt;0.001), hsa-miR-6749-5p (padj&lt;0.001). 173 microRNA differed in phMEN1 and control groups (11 microRNAs upregulated, 162 — downregulated). We detected several decreased microRNAs in phMEN1 that participate in tumor genesis: hsa-miR-625-3p (padj&lt;0.005), hsa-miR-3168 (padj=0,028), hsa-miR-302b-3p (padj&lt;0.001). Conclusion We found microRNAs, which could potentially become biomarkers in phMEN1 diagnosis. The results need to be validated using different measurement method with larger sample size. Likewise further assessment of plasma microRNA expression in genetically confirmed MEN1 patients is needed. Presentation: Monday, June 13, 2022 12:30 p.m. - 12:35 p.m., Monday, June 13, 2022 12:30 p.m. - 2:30 p.m." @default.
• W4308134630 created "2022-11-08" @default.
• W4308134630 creator A5013718888 @default.
• W4308134630 creator A5027014087 @default.
• W4308134630 creator A5031909199 @default.
• W4308134630 creator A5033215666 @default.
• W4308134630 creator A5035453919 @default.
• W4308134630 creator A5067539673 @default.
• W4308134630 date "2022-11-01" @default.
• W4308134630 modified "2023-10-16" @default.
• W4308134630 title "RF25 | PMON147 Plasma MicroRNA Expression in Phenocopy of Multiple Endocrine Neoplasia Type 1 Compared to Patients with Acromegaly and Primary Hyperparathyroidism: Potential Biomarkers of Multiple Endocrine Tumor Growth" @default.
• W4308134630 doi "https://doi.org/10.1210/jendso/bvac150.1211" @default.
• W4308134630 hasPublicationYear "2022" @default.
• W4308134630 type Work @default.
• W4308134630 citedByCount "0" @default.
• W4308134630 crossrefType "journal-article" @default.
• W4308134630 hasAuthorship W4308134630A5013718888 @default.
• W4308134630 hasAuthorship W4308134630A5027014087 @default.
• W4308134630 hasAuthorship W4308134630A5031909199 @default.
• W4308134630 hasAuthorship W4308134630A5033215666 @default.
• W4308134630 hasAuthorship W4308134630A5035453919 @default.
• W4308134630 hasAuthorship W4308134630A5067539673 @default.
• W4308134630 hasBestOaLocation W43081346301 @default.
• W4308134630 hasConcept C104317684 @default.
• W4308134630 hasConcept C12387725 @default.
• W4308134630 hasConcept C126322002 @default.
• W4308134630 hasConcept C127716648 @default.
• W4308134630 hasConcept C134018914 @default.
• W4308134630 hasConcept C143998085 @default.
• W4308134630 hasConcept C145059251 @default.
• W4308134630 hasConcept C2777433750 @default.
• W4308134630 hasConcept C2779053571 @default.
• W4308134630 hasConcept C2779469564 @default.
• W4308134630 hasConcept C2780103800 @default.
• W4308134630 hasConcept C2984496839 @default.
• W4308134630 hasConcept C41091548 @default.
• W4308134630 hasConcept C46699223 @default.
• W4308134630 hasConcept C502942594 @default.
• W4308134630 hasConcept C54355233 @default.
• W4308134630 hasConcept C60644358 @default.
• W4308134630 hasConcept C71315377 @default.
• W4308134630 hasConcept C71924100 @default.
• W4308134630 hasConcept C86803240 @default.
• W4308134630 hasConceptScore W4308134630C104317684 @default.
• W4308134630 hasConceptScore W4308134630C12387725 @default.
• W4308134630 hasConceptScore W4308134630C126322002 @default.
• W4308134630 hasConceptScore W4308134630C127716648 @default.
• W4308134630 hasConceptScore W4308134630C134018914 @default.
• W4308134630 hasConceptScore W4308134630C143998085 @default.
• W4308134630 hasConceptScore W4308134630C145059251 @default.
• W4308134630 hasConceptScore W4308134630C2777433750 @default.
• W4308134630 hasConceptScore W4308134630C2779053571 @default.
• W4308134630 hasConceptScore W4308134630C2779469564 @default.
• W4308134630 hasConceptScore W4308134630C2780103800 @default.
• W4308134630 hasConceptScore W4308134630C2984496839 @default.
• W4308134630 hasConceptScore W4308134630C41091548 @default.
• W4308134630 hasConceptScore W4308134630C46699223 @default.
• W4308134630 hasConceptScore W4308134630C502942594 @default.
• W4308134630 hasConceptScore W4308134630C54355233 @default.
• W4308134630 hasConceptScore W4308134630C60644358 @default.
• W4308134630 hasConceptScore W4308134630C71315377 @default.
• W4308134630 hasConceptScore W4308134630C71924100 @default.
• W4308134630 hasConceptScore W4308134630C86803240 @default.
• W4308134630 hasIssue "Supplement_1" @default.
• W4308134630 hasLocation W43081346301 @default.
• W4308134630 hasLocation W43081346302 @default.
• W4308134630 hasOpenAccess W4308134630 @default.
• W4308134630 hasPrimaryLocation W43081346301 @default.
• W4308134630 hasRelatedWork W2113441292 @default.
• W4308134630 hasRelatedWork W2963630908 @default.
• W4308134630 hasRelatedWork W3157376257 @default.
• W4308134630 hasRelatedWork W349240617 @default.
• W4308134630 hasRelatedWork W4205298097 @default.
• W4308134630 hasRelatedWork W4206901200 @default.
• W4308134630 hasRelatedWork W4225394350 @default.
• W4308134630 hasRelatedWork W4244106211 @default.
• W4308134630 hasRelatedWork W4289532954 @default.
• W4308134630 hasRelatedWork W4308134630 @default.
• W4308134630 hasVolume "6" @default.
• W4308134630 isParatext "false" @default.
• W4308134630 isRetracted "false" @default.
• W4308134630 workType "article" @default.